Patients in GO-BEFORE ( n = 637 , MTX-nave ) and GO-FORWARD ( n = 444 , MTX-inadequate response ) were randomised to placebo + MTX , golimumab 100 mg + placebo , golimumab 50 mg + MTX , or golimumab 100 mg + MTX .
